STOCK TITAN

ANI Pharmaceuticals (ANIP) Stock News

ANIP NASDAQ

ANI Pharmaceuticals, Inc. reports developments as a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses. Its Rare Disease portfolio includes Purified Cortrophin® Gel and ophthalmology products such as ILUVIEN® and YUTIQ®, while its generics portfolio includes products launched through FDA-approved abbreviated new drug applications.

ANI news commonly covers quarterly and annual financial results, guidance updates, product revenue trends, FDA approvals, generic product launches, clinical data publications, investor presentations, and capital allocation actions. Company updates also describe activity in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, along with manufacturing and commercialization execution in the United States.

Rhea-AI Summary

ANI Pharmaceuticals (ANIP) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 1, 2026. President and CEO Nikhil Lalwani and other executives will join the chat at 12:30 p.m. ET. Live and archived webcasts will be available in the Events and Presentations area of the company’s Investors section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ANI Pharmaceuticals (Nasdaq: ANIP) reported third-quarter 2026 net revenue of $290.8 million, up 27.6% from the prior-year quarter. GAAP net income available to common shareholders rose to $35.1 million, or $1.51 per diluted share, from $26.3 million, or $1.13. Cortrophin Gel revenue increased 36.1% to $138.7 million, although specialty pharmacy capacity constraints slowed revenue conversion.

ANI lowered 2026 Cortrophin guidance to $480–$500 million from $520–$540 million, narrowed total revenue guidance to $1,085–$1,125 million and raised adjusted earnings guidance. It also announced an offer for Egetis Therapeutics at SEK 11.25 per share, with an approximately SEK 5.6 billion offer value including outstanding incentive programs. Completion requires at least 90% shareholder acceptance and necessary regulatory approvals. ANI repurchased approximately $20.0 million of stock through November 2.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
-
Rhea-AI Summary

ANI Pharmaceuticals (Nasdaq: ANIP) announced a recommended public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion.

The offer includes shares at SEK 11.25 each, a 27% premium to the 60-day volume-weighted average price, plus convertible debt and warrants. Egetis’ board unanimously recommends acceptance; holders of approximately 42% of outstanding shares have conditionally committed to accept. Closing requires at least 90% shareholder acceptance and necessary regulatory approvals. Funding combines cash on hand and new JPMorgan Chase Bank debt.

Egetis’ EMCITATE is approved in the U.S. and Europe for peripheral thyrotoxicosis in patients with MCT8 deficiency. ANI estimates peak sales potential above $300 million in its approved indication; patent protection extends into mid-2045. The offer reflects estimated net proceeds from Egetis’ agreed $190.0 million voucher sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
Rhea-AI Summary

ANI Pharmaceuticals (ANIP) will participate in investor conference presentations and fireside chats on November 10 and November 17, 2026.

The Guggenheim Healthcare Innovation Conference session is at 1:30 p.m. ET; the Jefferies Global Healthcare Conference in London session is at 9:30 a.m. GMT, respectively. CEO Nikhil Lalwani and executive leadership members will participate. Live and archived webcasts will be available on the company’s investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none
-
Rhea-AI Summary

ANI Pharmaceuticals (ANIP) will release its third quarter 2026 financial results on November 5, 2026, at 8:00 a.m. ET. Nikhil Lalwani, Stephen P. Carey and Chris Mutz will host a webcast and conference call to discuss the results. The webcast replay will remain accessible for up to one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
-
Rhea-AI Summary

ANI Pharmaceuticals (Nasdaq: ANIP) has launched Duloxetine Delayed-Release Capsules, adding a generic version of Cymbalta to its product offerings. The capsules are available in 20, 30 and 60 mg strengths. The company said the launch provides another treatment alternative in a market with limited suppliers, with the aim of supporting stable supply.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
Rhea-AI Summary

ANI Pharmaceuticals (ANIP) announced that its Phase 4 SYNCHRONICITY eye-implant trial met both primary endpoints with statistical significance at six months. The U.S. open-label, single-arm study evaluated fluocinolone acetonide intravitreal implant 0.18 mg in patients with chronic non-infectious inflammation affecting the back of the eye who had responded to steroid therapy.

Among 108 patients, mean best-corrected visual acuity improved by 3.6 letters and central retinal thickness decreased by 157.5 microns at six months. At 24 months, the respective changes were +5.5 letters and −171.2 microns; 79.6% of study eyes had no inflammation recurrence. Treatment-related adverse events occurred in 29% of patients, and 7.4% required laser or surgical intervention to lower eye pressure. Cataract surgery occurred in 14.8% of study eyes. Results were presented on October 9, 2026, at the American Academy of Ophthalmology meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
-
Rhea-AI Summary

ANI Pharmaceuticals (Nasdaq: ANIP) will present Phase 4 SYNCHRONICITY trial data at the American Academy of Ophthalmology meeting on October 9, 2026. The late-breaking oral presentation during Uveitis Subspecialty Day in New Orleans will cover fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis affecting the back of the eye. SYNCHRONICITY is an open-label, single-arm trial, meaning treatment is known and there is no comparison group. Principal investigator David Almeida will present.

ANI also plans an on-demand ePoster presented by Christina Y Weng on Phase 4 NEW DAY analyses conducted after the trial, comparing baseline characteristics and efficacy in rescued and non-rescued patients with diabetic macular edema. An encore SYNCHRONICITY presentation by Victor Gonzalez is planned for January 21, 2027, at Hawaiian Eye & Retina.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary

ANI Pharmaceuticals (ANIP) received final FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg and 5 mg strengths.

The product is the generic version of reference listed drug Afinitor Disperz®, expanding ANI’s U.S.-focused generics portfolio with a technically demanding formulation. The company’s CEO said this approval demonstrates ongoing execution by the R&D team and supports momentum in the commercial portfolio.

The company reiterated that it remains on track to launch at least 15 new generic products in 2026, with Everolimus Tablets for Oral Suspension contributing to that target. U.S. annual sales for Everolimus Tablets for Oral Suspension totaled approximately $123 million based on July 2026 moving annual total IQVIA data, highlighting the market size of the reference product that ANI’s generic will compete in.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
Rhea-AI Summary

ANI Pharmaceuticals (ANIP)/b) announced that President and CEO Nikhil Lalwani and members of the executive leadership team will participate in fireside chats at three September 2026 investor conferences.These are the 2026 Wells Fargo Healthcare Conference on September 10 at 1:30 p.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 7:00 a.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 12:00 p.m. ET. Live and archived webcasts will be available in the Investors section of the company’s website under Events and Presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none

FAQ

What is the current stock price of ANI Pharmaceuticals (ANIP)?

ANI Pharmaceuticals (ANIP) last closed at $71.47.

What is the market cap of ANI Pharmaceuticals (ANIP)?

The market cap of ANI Pharmaceuticals (ANIP) is approximately $1.6B.